Core Insights - Kestra Medical Technologies, Ltd. has been named a finalist for the "Deal of the Year" at the 2026 GeekWire Awards, recognizing its significant impact in the technology ecosystem of the Pacific Northwest [1][2] - The nomination is primarily due to Kestra's successful initial public offering (IPO) in 2025, which has facilitated ongoing commercial expansion and innovation in its Cardiac Recovery System platform [2][3] - The recognition reflects the company's momentum and growth potential, as stated by the CEO, who emphasized the IPO's role in enhancing investment capabilities for advancing patient care standards [3] Company Overview - Kestra Medical Technologies specializes in wearable medical devices and digital healthcare, focusing on improving patient outcomes in cardiovascular disease through innovative monitoring and therapeutic technologies [4]

Company Overview March 2026 Disclaimer This presentation and the accompanying oral presentation (this "presentation") have been prepared by Kestra Medical Technologies, Ltd. (together with its subsidiaries and affiliates, the "Company") and are made solely for informational purposes only and not for any other purpose. Certain statements in this presentation are forward-looking statements. These statements relate to future events or the future performance of the Company, as well as its business strategy and ...

Kestra Medical Technologies FY Conference Summary Company Overview - **Company**: Kestra Medical Technologies (NasdaqGS:KMTS) - **Industry**: Medical Technology (MedTech) - **Market Focus**: Wearable medical devices, specifically the Cardiac Recovery Platform featuring the Assure wearable cardioverter-defibrillator (WCD) [3][4] Key Points and Arguments Market Opportunity - **Total Addressable Market (TAM)**: Approximately $10 billion in the U.S., with a larger market outside the U.S. [3] - **Current Market Penetration**: Estimated at $1 billion, indicating significant growth potential as the second entrant in a previously monopolized market [3] - **Patient Population**: About 850,000 patients diagnosed with low cardiac output annually, with only 120,000 currently served, highlighting underpenetration [11][12] Product and Technology - **Product**: Assure wearable cardioverter-defibrillator, designed for patients at risk of cardiac arrest, particularly post-myocardial infarction (MI) and heart failure patients [4][5] - **Clinical Efficacy**: Achieved a 100% conversion rate for lethal ventricular arrhythmias in clinical trials, emphasizing the device's effectiveness [9] - **Wearability**: Median wear time reported at over 23 hours a day, addressing compliance issues common in the WCD space [11] Clinical and Regulatory Milestones - **FDA Approval**: PMA approved in late 2021, with a full commercial launch starting in August 2022 [7] - **Post-Approval Study**: Conducted on 21,000 patients, demonstrating safety and efficacy, with a low false alarm rate critical for patient compliance [15] Strategic Partnerships and Innovations - **Partnership with Biobeat Technologies**: Aimed at integrating cuffless blood pressure monitoring into the Assure platform, addressing the needs of hypertensive patients [17][18] - **R&D Focus**: Concentrating on diagnostic monitoring capabilities and addressing comorbidities prevalent in the patient population [31] Commercial Strategy - **Sales Force Expansion**: Increased from 100 to a target of 130 sales representatives by the end of the fiscal year, enhancing market penetration [28] - **Insurance Coverage**: Over 290 million covered lives, achieving 90% coverage in the U.S., which is crucial for business model viability [19] Financial Performance and Projections - **Gross Margin**: Achieved approximately 50% in the last quarter, with expectations to exceed 70% as the business scales [22][34] - **Revenue Growth**: Experiencing over 50% growth in recent quarters, with projections for continued growth driven by market expansion and improved insurance coverage [22][23] Market Dynamics - **Market Growth Rate**: Currently estimated at 11-12%, with potential for acceleration due to guideline changes and increased awareness among physicians [23][26] - **Competitive Landscape**: Kestra's entry has revitalized the market, prompting competitors to shift focus towards market development [26] Additional Important Insights - **Patient Compliance**: Addressing the challenge of getting patients to wear the device consistently is critical for the success of the WCD category [11] - **Market Development Activities**: Increased educational events to raise awareness and drive adoption among healthcare providers [39] - **Long-Term Vision**: Kestra aims to leverage its clinical data and innovative platform to drive significant growth in the MedTech space [24][37] This summary encapsulates the key insights from the conference, highlighting Kestra Medical Technologies' strategic positioning, product efficacy, market opportunities, and growth potential within the MedTech industry.